Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A4 | Q9H015 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7254623 | 1.00 | SLC22A4 (0.35) | SLC22A4POLBALPLALPGGAA | |
| Water SCHEMBL15121340 | 0.98 | SLC22A4 (0.34) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL19499931 | 0.88 | SLC22A4 (0.35) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL188141 | 0.87 | SLC22A4 (0.49) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL19928438 | 0.83 | SLC22A4 (0.35) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL18072719 | 0.80 | APAF1 (0.41) | POLB | |
| SCHEMBL18052196 | 0.80 | APAF1 (0.41) | POLB | |
| SCHEMBL1065159 | 0.76 | SLC7A5 (0.45) | POLB | |
| SCHEMBL19499928 | 0.76 | SLC22A4 (0.32) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL1670197 | 0.74 | CYP3A4 (0.33) | SLC22A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197683-A1 | USE OF ERGOTHIONEINE (EGT) FOR PREVENTION AND TREATMENT OF SEPSIS | JIANGSU UNIVERSITY (CN) | 2024-06-20 | — | — | US | disclosed |
| US-20150225755-A1 | Ergothioneine Production Through Metabolic Engineering | ERGO HEALTH LLC | 2015-08-13 | — | — | US | disclosed |
| US-7767826-B2 | Process for the synthesis of L-(+)-ergothioneine | PHARMATECH INTERNATIONAL, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767826-B2 | Process for the synthesis of L-(+)-ergothioneine | PHARMATECH INTERNATIONAL, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090093642-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | PHARMATECH INTERNATIONAL, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090093642-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | PHARMATECH INTERNATIONAL, INC. | 2009-04-09 | — | — | US | disclosed |
| US-6635802-B1 | Culturing mammalian cell population in serum starvation media containing apoptosis inhibitor to increase number of cells at G0/G1 stage of cell cycle within cell population, increasing number of nuclear transfer competent cells | THE TEXAS A&M UNIVERSITY SYSTEM | 2003-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225755-A1 | Ergothioneine Production Through Metabolic Engineering | HNMT, SHMT1, TST | SLC22A4 447/4885POLB 3901/4885ALPL 3279/4885 |
| US-20090093642-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | TTPA, DTYMK, TST | SLC22A4 2504/4885POLB 1148/4885ALPL 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.